The over 5% surge, hitting an intraday high of ₹6,255 and closing at ₹6,225, is clearly driven by the positive sentiment following Citi’s reaffirmed ‘Buy’ rating and the new target price.
Capacity Expansion: Divi’s is ramping up its production capabilities, positioning itself as a primary supplier in the pharma sector.
Pipeline Growth: The company is adding Orforglipron, Eli Lilly’s potential best-in-class oral GLP-1, to its pipeline. This move is expected to contribute over $800 million in GLP-1 revenue by 2030.